References
- Wang, S.D. (2013) Opportunities and challenges of clinical research in the bigdataera: from RCT to BCT. J. Thorac. Dis., 5, 721-723. https://doi.org/10.3978/j.issn.2072-1439.2013.06.24
- Liu, M., Melton, B.L., Ator, G. and Waitman, L.R. (2017) Integrating medication alert data into a clinical data repository to enable retrospective study of drug interaction alerts in clinical practice. AMIA Jt. Summits Transl. Sci. Proc., 2017, 213-220.
- Jaspers, M.W., Smeulers, M., Vermeulen, H. and Peute, L.W. (2011) Effects of clinical decision-support systems on practitioner performance and patient outcomes: a synthesis of high-quality systematic review findings. J. Am. Med. Inform. Assoc., 18, 327-334. https://doi.org/10.1136/amiajnl-2011-000094
- Murdoch, T. and Detsky, A. (2013) The inevitable application of big data to healthcare. JAMA, 309, 1351-1352. https://doi.org/10.1001/jama.2013.393
- Springate, D.A., Kontopantelis, E., Ashcroft, D.M., Olier, I., Rosa Parisi, R., Chamapiwa, E. and Reeves, D. (2014) Clinical codes: an online clinical codes repository toimprove the validity and reproducibility of researchusing electronic medical records. PLoS ONE, 9, e99825. https://doi.org/10.1371/journal.pone.0099825
- Cheetham, T.C., Lee, J., Hunt, C.M., Niu, F., Reisinger, S., Murray, R., Powell, G. and Papay, J. (2014) An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data. Pharmacoepidemiol. Drug Saf., 23, 601-608. https://doi.org/10.1002/pds.3531
- Bjornsson, E.S. (2016) Hepatotoxicity by drugs: the most common implicated agents. Int. J. Mol. Sci., 17, 224. https://doi.org/10.3390/ijms17020224
- Kullak-Ublick, G.A., Andrade, R.J., Merz, M., End, P. and Benesic, A. (2017) Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut, 66, 1154-1164. https://doi.org/10.1136/gutjnl-2016-313369
- Pirmohamed, M., James, S. and Meakin, S. (2004) Adverse drug reaction as cause of admission to hospital: prospective analysis of 18820 patients. BMJ, 329, 15-19. https://doi.org/10.1136/bmj.329.7456.15
- Lazarous, J., Pomeranz, B. and Corey, P.N. (1998) Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA, 279, 1200-1205. https://doi.org/10.1001/jama.279.15.1200
- Kohn, L.T., Corrgan, J.M. and Donaldson, M.S. (2000) To Error in Human; Building a Safer Health System, National Academy Press, Washington, DC.
- Shin, J., Hunt, D.M., Suzuki, A., Papay, J.I., Beach, K.J. and Cheetham, T.C. (2013) Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data. Pharmacoepidemiol. Drug Saf., 22, 190-198. https://doi.org/10.1002/pds.3388
- Lin, K.J. and Schneeweiss, S. (2016) Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs. Clin. Pharmacol. Ther., 100, 147-157. https://doi.org/10.1002/cpt.359
- Andreea, F. and Marius, B. (2009) Adverse drug reactions in clinical practice: a causality assessment of a case of drug-induced pancreatitis. J. Gastrointest. Liver Dis., 18, 353-358.
- Jha, A.K., Kuperman, G.J., Teich, J.M., Leape, L., SHea, B., Rittenberg, E., Burdick, E., Seger, D.L., Vander Vliet, M., Bates, D.W. (1998) Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J. Am. Med. Inform. Assoc., 5, 305-314. https://doi.org/10.1136/jamia.1998.0050305
- Tisdale, J.E. and Miller, D.A. (2005) Drug-Induced Diseases: Prevention, Detection and Management, American Society of Health-System Pharmacist Press, Bethesda, Maryland, pp. 1004-1007.
- Lee, Y.H., Kang, U.G. and Park, R.W. (2008) Development of adverse drug event surveillance system using BI technology. Int. J. Contents, 9, 106-113.
- Miller, T.P., Ki, Y., Getz, K.D., Dudley, J., Burrows, E., Pennington, J., Ibrahimova, A., Fisher, B.T., Baqatell, R., Seif, A.E., Grundmeier, R. and Aplenc, R. (2017) Using electronic medical record data to report laboratory adverse events. Br. J. Haematol., 177, 283-286. https://doi.org/10.1111/bjh.14538
- Pandit, A., Sachdeva, T. and Bafna, P. (2012) Drug-induced hepatotoxicity: a review. J. Appl. Pharm. Sci., 02, 233-243.
- Mauben, M., Madigan, D. and Gerritis, C.M. (2007) The role of data mining in pharmacovigilance. Exp. Opin. Drug Saf., 14, 929-948.
- Phansalkar, S., Hoffman, J.M., Nebeker, J.R. and Hurdle, J.F. (2007) Pharmacists versus nonpharmacists in adverse drug event detection: a meta-analysis and systematic review. Am. J. Health Syst. Pharm., 64, 842-849. https://doi.org/10.2146/ajhp060335
- Phansalkar, S., Hoffman, J.M., Hurdle, J.F. and Patel, V.L. (2009) Understanding pharmacist decision making for adverse drug event (ADE) detection. J. Eval. Clin. Pract., 15, 266-275. https://doi.org/10.1111/j.1365-2753.2008.00992.x
- Tojios, S. and Fontana, R.J. (2011) Mechanisms of drug-induced liver injury: from bedside to bench. Nat. Rev. Gastroenterol. Hepatol., 8, 202-211. https://doi.org/10.1038/nrgastro.2011.22
- Manuel, D.G., Rosella, L.C. and Stukel, T.A. (2010) Importance of accurately identifying disease in studies using electronic health records. BMJ, 341, c4226. https://doi.org/10.1136/bmj.c4226
- Pratt, N., Cham, E.W., Choi, N.K., Kimura, M., Kimura, T., Kubota, K., Lai, E.C., Man, L.L., Ooba, N., Park, B.J., Sato, T., Shin, J.Y., Wong, I.C., Kao Yang, Y.H. and Roughead, E.E. (2015) Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries. Pharmacoepidemiol. Drug Saf., 24, 858-864. https://doi.org/10.1002/pds.3780
- Scholl, J.H.G., van Hunsel, F.P.A.M., Hak, E. and van Puijenbroek, E.P. (2017) A prediction model-based algorithm for computer-assisted database screening of adverse drug reactions in the Netherlands. Pharmacoepidemiol. Drug Saf., 27, 199-205. https://doi.org/10.1002/pds.4364
- Chen, X., Wang, Y., Wang, P., Lian, B., Li, C., Wamg, J., Li, X. and Jiang, W. (2015) Systematic analysis of the associations between adverse drug reactions and pathways. Biomed. Res. Int., 2015, 670949.
- Kohonen, P., Parkkinen, J.A., Willinghaegen, E.L., Ceder, R., Wennerbern, K., Kaski, S. and Grafstrom, R.C. (2017) A transcriptomics data-driven gene space accurately predicts liver cytopathology and drug-induced liver injury. Nat. Commun., 8, 15932. https://doi.org/10.1038/ncomms15932
- Koutkias, V.G. and Jaulent, M.-C. (2015) Computational approaches for pharmacovigilance signaldetection: toward integrated and semantically-enriched frameworks. Drug Saf., 38, 219-232. https://doi.org/10.1007/s40264-015-0278-8
- Carr, D.F. and Pirmohamed, M. (2017) Biomarkers of adverse drug reactions. Exp. Biol. Med. (Maywood), 243, 291-299. https://doi.org/10.1177/1535370217733425
- Xu, Q., Higgins, T. and Cembrowski, G.S. (2015) Limiting the testing of AST: a diagnostically nonspecific enzyme. Am. J. Clin. Pathol., 144, 423-426. https://doi.org/10.1309/AJCPO47VAWYRIDHG
- Alfirevic, A., Neely, D., Armitage, J., Chinoy, H., Cooper, R.G., Laaksonen, R., Carr, D.F., Bloch, K.M., Fahy, J., Hanson, A., Yue, Q.Y., Wadelius, M., Maitland-van Der Zee, A.H., Voora, D., Psaty, B.M., Paimer, C.N. and Pirmohamed, M. (2014) Phenotype standardization for statin-induced myotoxicity. Clin. Pharmacol. Ther., 96, 470-476. https://doi.org/10.1038/clpt.2014.121
- Duma, R.J. and Siegel, A.L. (1965) Serum creatinine phohphokinase in acute myocardical infarction: diagnostic value. Arch. Intern. Med., 115, 443-451. https://doi.org/10.1001/archinte.1965.03860160069011
- Kindermann, W. (2016) Creatine kinase levels after exercise. Dtsch. Arztebl. Int., 113, 344.
- Wilke, R.A., Lin, D.W., Roden, D.M., Watkins, P.B., Flockhart, D., Zineh, I., Giacomini, K.M. and Krauss, R.M. (2007) Identifying genetic risk factors for serious adverse drug reactions:current progress and challenges. Nat. Rev. Drug Discov., 6, 904-916. https://doi.org/10.1038/nrd2423
- Redwood, A.J., Pavlos, R.K., White, K.D. and Phillips, E.J. (2018) Human leukocyte antigens: key regulators of T-cell mediated drug hypersensitivity. HLA, 91, 3-16. https://doi.org/10.1111/tan.13183
- Wang, C.-W., Chung, W.-H. and Hung, S.-I. (2017) Genetics of adverse drug reactions. eLS, 1-10.
- Lea, J.D., Clarke, J.I., McGuire, N. and Antoine, D.J. (2016) Redox-dependent HMGB1 isoforms as pivotal co-ordinators of drug-induced liver injury: mechanistic biomarkers and therapeutic targets. Antioxid. Redox. Signal., 24, 652-665. https://doi.org/10.1089/ars.2015.6406
- Chan, S.L., Jin, S., Loh, M. and Brunham, L.R. (2015) Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity. Pharmacogenomics, 16, 1161-1178. https://doi.org/10.2217/PGS.15.54
- Nelson, M.R., Bacanu, S.A., Mosteller, M., Li, L., Bowman, C.E., Roses, A.D., Lai, E.H. and Ehm, M.G. (2009) Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J., 9, 23-33. https://doi.org/10.1038/tpj.2008.4
- Pichler, W.J. (2003) Delayed drug hypersensitivity reactions. Ann. Intern. Med., 139, 683-693. https://doi.org/10.7326/0003-4819-139-8-200310210-00012
- Ling, H., Fabbri, M. and Calin, G.A. (2013) MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov., 12, 847-865. https://doi.org/10.1038/nrd4140
- Matsui, M. and Corey, D.R. (2017) Non-coding RNAs as drug targets. Nat. Rev. Drug Discov., 16, 167-179. https://doi.org/10.1038/nrd.2016.117
- Fu, X.D. (2014) Non-coding RNA: a new frontier in regulatory biology. Natl. Sci. Rev., 1, 190-204. https://doi.org/10.1093/nsr/nwu008
- Maurano, M.T., Humbert, R., Rynes, E., Thurman, R.E., Haugen, E., Wang, H., Reynolds, A.P., Sandstrom, R., Qu, H., Brody, J., Shafer, A., Neri, F., Lee, K., Kutyavin, T., Stehling-Sun, S., Johnson, A.K., Canfield, T.K., Giste, E., Diegel, M., Bates, D., Hansen, R.S., Neph, S., Sabo, P.J., Heimfeld, S., Raubitschek, A., Ziegler, S., Cotsapas, C., Sotoodehnia, N., Glass, I., Sunyaev, S.R., Kaul, R. and Stamatoyannopoulos, J.A. (2012) Systematic localization of common disease-associated variation in regulatory DNA. Science, 337, 1190-1195. https://doi.org/10.1126/science.1222794
- Esteller, M. (2011) Non-coding RNAs in human disease. Nat. Rev. Genet., 12, 861-874. https://doi.org/10.1038/nrg3074
- Croce, C.M. (2009) Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet., 10, 704-714. https://doi.org/10.1038/nrg2634
- Nakajima, M. and Yokoi, T. (2011) MicroRNAs from biology to future pharmacotherapy: regulation of cytochrome P450s and nuclear receptors. Pharmacol. Ther., 131, 330-337. https://doi.org/10.1016/j.pharmthera.2011.04.009
- Yu, A.M. (2009) Role of microRNAs in the regulation of drug metabolism and disposition. Exp. Opin. Drug Metab. Toxicol., 5, 1513-1528. https://doi.org/10.1517/17425250903307448
- Zanger, U.M. and Schwab, M. (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther., 138, 103-141. https://doi.org/10.1016/j.pharmthera.2012.12.007
- Pan, Y.Z., Gao, W. and Yu, A.M. (2009) MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab. Dispos., 37, 2112-2117. https://doi.org/10.1124/dmd.109.027680
- Lu, Y. and Cederbaum, A.I. (2008) CYP2E1 and oxidative liver injury by alcohol. Free Radic. Biol. Med., 44, 723-738. https://doi.org/10.1016/j.freeradbiomed.2007.11.004
- Mohri, T., Nakajima, M., Fukami, T., Takamiya, M., Aoki, Y. and Yokoi, T. (2010) Human CYP2E1 is regulated by miR-378. Biochem. Pharmacol., 79, 1045-1052. https://doi.org/10.1016/j.bcp.2009.11.015
- Song, K.H., Li, T., Owsley, E. and Chiang, J.Y. (2010) A putative role of micro RNA in regulation of cholesterol 7alpha-hydroxylase expression in human hepatocytes. J. Lipid Res., 51, 2223-2233. https://doi.org/10.1194/jlr.M004531
- Komagata, S., Nakajima, M., Takagi, S., Mohri, T., Taniya, T. and Yokoi, T. (2009) Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol. Pharmacol., 76, 702-709. https://doi.org/10.1124/mol.109.056986
- Lin, H., Ewing, L.E., Koturbash, I., Gurley, B.J. and Miousse, I.R. (2017) MicroRNAs as biomarkers for liver injury: current knowledge, challenges and future prospects. Food Chem. Toxicol., 110, 229-239. https://doi.org/10.1016/j.fct.2017.10.026
- Marrone, A.K., Beland, F.A. and Pogribny, I.P. (2015) The role for microRNAs in drug toxicity and in safety assessment. Exp. Opin. Drug Metab. Toxicol., 11, 601-611. https://doi.org/10.1517/17425255.2015.1021687
- Antoine, D.J., Dear, J.W., Lewis, P.S., Platt, V., Coyle, J., Masson, M., Thanacoody, R.H., Gray, A.J., Webb, D.J., Moggs, J.G., Bateman, D.N., Goldring, C.E. and Park, B.K. (2013) Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology, 58, 777-787. https://doi.org/10.1002/hep.26294
- Howell, L.S., Ireland, L., Park, B.K. and Goldring, C.E. (2018) MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury. Exp. Rev. Mol. Diagn., 18, 47-54. https://doi.org/10.1080/14737159.2018.1415145
- Sato, S., Ichihara, A., Jinnin, M., Izuno, Y., Fukushima, S. and Ihn, H. (2015) Serum miR-124 up-regulation as a disease marker of toxic epidermal necrolysis. Eur. J. Dermatol., 25, 457-462. https://doi.org/10.1684/ejd.2015.2621
- Ichihara, A., Wang, Z., Jinnin, M., Izuno, Y., Shimozono, N., Yamane, K., Fujisawa, A., Moriya, C., Fukushima, S., Inoue, Y., Shimozono, N., Yamane, K., Fujisawa, A., Moriya, C., Fukushima, S., Inoue, Y. and Ihn, H. (2014) Upregulation of miR-18a-5p contributes to epidermal necrolysis in severe drug eruptions. J. Allergy Clin. Immunol., 133, 1065-1074. https://doi.org/10.1016/j.jaci.2013.09.019
- Williams, S.A., Murthy, A.C., DeLisle, R.K., Hyde, C., Malarstig, A., Ostroff, R., Weiss, S.J., Segal, M.R. and Ganz, P. (2018) Improving assessment of drug safety through proteomics: early detection and mechanistic characterization of the unforeseen harmful effects of torcetrapib. Circulation, 137, 999-1010. https://doi.org/10.1161/CIRCULATIONAHA.117.028213
- Zhou, H., Gao, M. and Skolnick, J. (2015) Comprehensive prediction of drug-protein interactions and side effects for the human proteome. Sci. Rep., 5, 11090. https://doi.org/10.1038/srep11090
- Huang, L.C., Wu, X. and Chen, J.Y. (2013) Predicting adverse drug reaction profiles by integrating protein interaction networks with drug structures. Proteomics, 13, 313-324. https://doi.org/10.1002/pmic.201200337
- Ge, F. and He, Q.Y. (2009) Genomic and proteomic approaches for predicting toxicity and adverse drug reactions. Exp. Opin. Drug Metab. Toxicol., 5, 29-37. https://doi.org/10.1517/17425250802661895
- Wilkins, M.R. (2002) What do we want from proteomics in the detection and avoidance of adverse drug reactions. Toxicol. Lett., 127, 245-249. https://doi.org/10.1016/S0378-4274(01)00506-9
- Amadoz, A., Sebastian-Leon, P., Vidal, E., Salavert, F. and Dopazo, J. (2015) Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity. Sci. Rep., 5, 18494. https://doi.org/10.1038/srep18494
- Frueh, F.W. (2010) Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice. Pharmacogenomics, 11, 657-660. https://doi.org/10.2217/pgs.10.46
- Ventola, C.L. (2011) Pharmacogenomics in clinical practice: reality and expectations. P T, 36, 412-450.
- Madian, A.G., Wheeler, H.E., Jones, R.B. and Dolan, M.E. (2012) Relating human genetic variation to variation in drug responses. Trends Genet., 28, 487-495. https://doi.org/10.1016/j.tig.2012.06.008
- Ventola, C.L. (2013) Role of pharmacogenomic biomarkers in predicting and improving drug response: part 1: the clinical significance of pharmacogenetic variants. P T, 38, 545-560.
- Trent, R.J. (2010) Pathology practice and pharmacogenomics. Pharmacogenomics, 11, 105-111. https://doi.org/10.2217/pgs.09.150
- Ma, J.D., Lee, K.C. and Kuo, G.M. (2012) Clinical application of pharmacogenomics. J. Pharm. Pract., 25, 417-427. https://doi.org/10.1177/0897190012448309
- Squassina, A., Manchia, M., Manolopoulos, V.G., Artac, M., Lappa-Manakou, C., Karkabouna, S., Mitropoulos, K., Del Zompo, M. and Patrinos, G.P. (2010) Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics, 11, 1149-1167. https://doi.org/10.2217/pgs.10.97
- Vogenberg, F.R., Isaacson Barash, C. and Pursel, M. (2010) Personalized medicine: part 1: evolution and development into theranostics. P T, 35, 560-576.
- Gervasini, G., Benitez, J. and Carrillo, J.A. (2010) Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur. J. Clin. Pharmacol., 66, 755-774. https://doi.org/10.1007/s00228-010-0857-7
- Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, I., Lathrop, M. and Collins, R. (2008) SLCO1B1 variants and statin-induced myopathy--a genomewide study. N. Engl. J. Med., 359, 789-799. https://doi.org/10.1056/NEJMoa0801936
- Flockhart, D.A., O'Kane, D., Williams, M.S., Watson, M.S., Flockhart, D.A., Gage, B., Gandolfi, R., King, R., Lyon, E., Nussbaum, R., O'Kane, D., Schulman, K., Veenstra, D., Williams, M.S., Watson, M.S.; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use (2008) Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet. Med., 10, 139-150. https://doi.org/10.1097/GIM.0b013e318163c35f
- Scott, S.A. (2011) Personalizing medicine with clinical pharmacogenetics. Genet. Med., 13, 987-995. https://doi.org/10.1097/GIM.0b013e318238b38c
- Taneja, I., Reddy, B. and Damhorst, G. (2017) Combining biomarkers with EMR data to identify patients in different phases of sepsis. Sci. Rep., 7, 10800. https://doi.org/10.1038/s41598-017-09766-1
- Crews, K.R., Hicks, J.K., Pui, C.H., Relling, M.V. and Evans, W.E. (2012) Pharmacogenomics and individualized medicine: translating science into practice. Clin. Pharmacol. Ther., 92, 467-475.
- Jiang, X.Y., Zhang, Q., Chen, P., Li, S.Y., Zhang, N.N., Chen, X.D., Wang, G.C., Wang, H.B., Zhuang, M.Q. and Lu, M. (2012) CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin. J. Clin. Pharm. Ther., 37, 719-723. https://doi.org/10.1111/j.1365-2710.2012.01372.x
- Zhu, M., Qiu, S., Zhang, X., Wang, Y., Souraka, T.D.M., Wen, X., Liang, C. and Tu, J. (2018) The associations between CYP24A1 polymorphisms and cancer susceptibility: a meta-analysis and trial sequential analysis. Pathol. Res. Pract., 214, 53-63. https://doi.org/10.1016/j.prp.2017.11.014